Universita′ Degli Studi Di Milano

The Noguchi Institute

Sandro Sonnino

Jin-Ichi Inokuchi

Hirotaka Kanoh

Elena Chiricozzi

Oligosaccharides are for use in the treatment of neurodegenerative diseases of the central nervous system, in particular Parkinson's disease, and to pharmaceutical compositions including one or more of the oligosaccharides.

Oligosaccharides for use in the treatment of Parkinson's disease

The agent for inhibiting inflammation promoted by GM3 of the present invention comprises a substance that inhibits inflammation promoted by GM3 as an active ingredient. The substance which inhibits inflammation promoted by GM3 is preferably a ganglioside having 2 or more of sialic acids. The ganglioside having 2 or more of sialic acids is at least one kind of ganglioside selected from the group consisting of GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c, and GP1c. Further, the substance which inhibits inflammation promoted by GM3 has a structure represented by the following formula (1): [In the formula (1), Rrepresents a glycan constituting ganglioside GM3, R&#x2014;C(&#x2550;O)&#x2014; represents a fatty acid residue having 18 or less of carbon atoms, or an unsaturated fatty acid residue having 20 or more of carbon atoms.]

Growing community of inventors

Milan, Italy

Sandro Sonnino